Affordable Access

Access to the full text

Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis

Authors
  • Hayashi, Keigo1
  • Sada, Ken-Ei1
  • Asano, Yosuke1
  • Asano, Sumie Hiramatsu1
  • Yamamura, Yuriko1
  • Ohashi, Keiji1
  • Morishita, Michiko1
  • Watanabe, Haruki1
  • Narazaki, Mariko1
  • Matsumoto, Yoshinori1
  • Wada, Jun1
  • 1 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama City, 700-8558, Japan , Okayama City (Japan)
Type
Published Article
Journal
Scientific Reports
Publisher
Springer Nature
Publication Date
Oct 30, 2020
Volume
10
Issue
1
Identifiers
DOI: 10.1038/s41598-020-75655-9
Source
Springer Nature
License
Green

Abstract

Renal impairment is a major concern in patients taking high-dose methotrexate (MTX) for malignancy, but it has not been fully explored in rheumatoid arthritis (RA) patients taking low-dose MTX. This study aimed to elucidate the dose-dependent effects of MTX on the renal function of patients with RA. We retrospectively reviewed 502 consecutive RA patients who were prescribed MTX for ≥ 1 year at Okayama University Hospital between 2006 and 2018. The primary outcome was the change in estimated glomerular filtration rate (eGFR) over 1 year. The association between MTX dosage (< 8, 8–12, and ≥ 12 mg/week) and the change in eGFR was evaluated using multiple linear regression analysis with adjustment for possible confounding factors including age, sex, disease duration, body weight, comorbidity, baseline eGFR, concomitant treatment, and disease activity. Mean patient age was 63 years; 394 (78%) were female. Median disease duration was 77 months, while mean MTX dosage was 8.6 mg/week. The last 1-year change of eGFR (mean ± SD) in patients treated with MTX < 8 (n = 186), 8–12 (n = 219), ≥ 12 mg/week (n = 97) decreased by 0.2 ± 7.3, 0.6 ± 8.6, and 4.5 ± 7.9 mL/min/1.73 m2/year, respectively (p < 0.0001). After adjustment for the confounding factors, MTX ≥ 12 mg/week was still correlated with a decrease in 1-year eGFR (beta-coefficient: − 2.5; 95% confidence interval, − 4.3 to − 0.6; p = 0.0089) in contrast to MTX 8–12 mg/week. Careful monitoring of renal function is required in patients with MTX ≥ 12 mg/week over the course of RA treatment regardless of disease duration.

Report this publication

Statistics

Seen <100 times